Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma

Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection

(2014) P R A Buijs et al.   CANCER GENE THERAPY

Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy

(2014) Fuliang Bai et al.   IMMUNOLOGY LETTERS

Influence of type-I Interferon receptor expression level on the response to type-I Interferons in human pancreatic cancer cells

(2014) Stephanie Booy et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy

(2014) D. Zamarin et al.   Science Translational Medicine

Prostate-Specific Antigen-Retargeted Recombinant Newcastle Disease Virus for Prostate Cancer Virotherapy

(2013) R. Shobana et al.   JOURNAL OF VIROLOGY

Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β

(2012) S Naik et al.   CANCER GENE THERAPY

Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions

(2012) Dmitriy Zamarin et al.   Future Microbiology

Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: Role of type I interferon signaling

(2012) Megan Moerdyk-Schauwecker et al.   VIROLOGY

Evasion of Influenza A Viruses from Innate and Adaptive Immune Responses

(2012) Carolien E. van de Sandt et al.   Viruses-Basel

Type I interferons as radiosensitisers for pancreatic cancer

(2011) Marjolein J.M. Morak et al.   EUROPEAN JOURNAL OF CANCER

Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancer

(2010) Pingdong Li et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection

(2010) John P. Neoptolemos et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Antitumor efficacy of viral therapy using genetically engineered Newcastle disease virus [NDV(F3aa)-GFP] for peritoneally disseminated gastric cancer

(2010) Kyo Young Song et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Genetically Engineered Oncolytic Newcastle Disease Virus Effectively Induces Sustained Remission of Malignant Pleural Mesothelioma

(2010) G. R. Silberhumer et al.   MOLECULAR CANCER THERAPEUTICS

Intramuscular inoculation of calves with an experimental Newcastle disease virus-based vector vaccine elicits neutralizing antibodies against Rift Valley fever virus

(2010) J. Kortekaas et al.   VACCINE

Genetically engineered Newcastle disease virus for malignant melanoma therapy

(2009) D Zamarin et al.   GENE THERAPY

Evaluation of an Attenuated Vesicular Stomatitis Virus Vector Expressing Interferon-β for Use in Malignant Pleural Mesothelioma: Heterogeneity in Interferon Responsiveness Defines Potential Efficacy

(2009) Vassiliki Saloura et al.   HUMAN GENE THERAPY

Enhancement of Oncolytic Properties of Recombinant Newcastle Disease Virus Through Antagonism of Cellular Innate Immune Responses

(2009) Dmitriy Zamarin et al.   MOLECULAR THERAPY

Engineered Newcastle Disease Virus as an Improved Oncolytic Agent Against Hepatocellular Carcinoma

(2009) Jennifer Altomonte et al.   MOLECULAR THERAPY

Recombinant Newcastle disease virus expressing human interleukin-2 serves as a potential candidate for tumor therapy

(2008) Heng Zhao et al.   VIRUS RESEARCH